|Videos|July 18, 2014
Optimizing Checkpoint Inhibition in NSCLC
Advertisement
Episodes in this series
For High-Definition, Click
The response rate with PD-1 inhibition in non-small cell lung cancer (NSCLC) is approximately 20% to 40%, depending on PD-L1 status. For patients who do not respond to single-agent PD-1 inhibition, combination strategies could be utilized to further improve outcomes.
The Lung-MAP study is currently assessing various treatment options based on molecular characteristics. In addition to immunotherapy, this study will also assess platinum-based chemotherapy.
View the video, to hear the discussion.
Advertisement
Related to this article
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The phase 3 OptiTROP-Lung06 trial showed a PFS improvement with sac-TMT plus pembrolizumab in PD-L1–negative NSCLC.
The FDA has approved selpercatinib for RET fusion–positive advanced solid tumors.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
2
Alpha DaRT Plus Pembrolizumab Yields 100% ORR in Elderly Recurrent or Metastatic HNSCC
3
Longer-Term Data Help Shape TKI Selection in ROS1+ and ALK+ NSCLC
4
Experts Revisit the Most Notable Data in GU Oncology From ASCO 2026
5